Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study
| العنوان: | Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study |
|---|---|
| المؤلفون: | Hidetoshi Yasuoka, Atsushi Naganuma, Eishin Kurihara, Tsutomu Kobatake, Masashi Ijima, Yuki Tamura, Yuhei Suzuki, Takashi Hoshino, Fumiya Ishida, Hisashi Hosaka, Takeshi Hatanaka, Sachiko Yoshida, Ryusuke Aihara, Yasuo Hosouchi, Norihiro Ishii, Kenichiro Araki, Ken Shirabe, Toshio Uraoka, Satoru Kakizaki |
| المصدر: | Oncology. 100:449-459 |
| بيانات النشر: | S. Karger AG, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Male, Cancer Research, Neutropenia, Leucovorin, General Medicine, Middle Aged, Irinotecan, Pancreatic Neoplasms, Oncology, Antineoplastic Combined Chemotherapy Protocols, Liposomes, Humans, Camptothecin, Female, Fluorouracil, Aged, Retrospective Studies |
| الوصف: | Introduction: This retrospective study investigated the efficacy and safety of nano-liposomal irinotecan (nal-IRI) plus 5-fluorouracil/L-leucovorin (5-FU/l-LV) treatment in the second-line or later setting for advanced pancreatic cancer under real-world conditions. Methods: Between June 2020 and September 2021, a total of 44 patients with unresectable advanced pancreatic cancer treated with nal-IRI + 5-FU/l-LV in our affiliated hospitals were included. The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated. Results: The median age was 68 (interquartile range 62–73) years old, and 22 patients (50.0%) were male. Concerning tumor factors, 9 patients (20.5%) had local advanced disease and 35 patients (79.5%) had metastases. Twenty-five of the 44 patients were receiving second-line treatment, and 19 were receiving third-line or later treatment. The median overall survival (OS) and progression-free survival were 9.0 (range, 0.7–15.4) months and 4.4 (range, 0.6–15.4) months, respectively. The overall response rate was 5.3%. The disease control rate was 44.7%. Patients with a neutrophil-to-lymphocyte ratio of ≥2.7 had a significant risk of a poor OS (HR = 0.275, p = 0.017). Adverse events were manageable, although gastrointestinal symptoms and neutropenia were observed. The most common grade ≥3 adverse event was neutropenia, which was reported in 20% of patients. Conclusions: Nal-IRI + 5-FU/l-LV therapy was considered to be a useful regimen as second-line or later treatment for unresectable advanced pancreatic cancer, even in clinical practice. |
| تدمد: | 1423-0232 0030-2414 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e188d894a7f9bafd02d2afd47ea6b33c https://doi.org/10.1159/000525742 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....e188d894a7f9bafd02d2afd47ea6b33c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14230232 00302414 |
|---|